Largest BioTech Public Companies in Finland

Company	HQ	Description	Sectors	Stock Price	1Y Perf.	Market Cap	EV	EV/Revenue	EV/EBITDA
Orion		Orion Oyj is a globally operating Finnish pharmaceutical company that…Orion Oyj is a globally operating Finnish pharmaceutical company that develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company predominantly focuses on treatments for central nervous system disorders, oncology, and respiratory diseases. Orion's customers include specialists and general practitioners, veterinarians, pharmacies, hospitals, and laboratories. Orion mainly serves Finland but also has a presence in other European countries, North America and other countries.	Biopharmaceuticals	$79	+8%	$11B	$11B	5.0x	13.8x
Faron Pharmaceuticals		Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company…Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company developing novel treatments for medical conditions with unmet needs. The company has a pipeline based on the receptors involved in the regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the company's investigational intravenous interferon beta-1a is an anti-viral and anti-inflammatory agent, being tested for the prevention of complications that arise from cytokine release syndrome, or hyperinflammatory conditions.	Biopharmaceuticals	$1	-77%	$126M	$140M	371.3x	(6.1x)
Nanoform		Nanoform Finland PLC is a nanoparticle medicine-enabling company. The…Nanoform Finland PLC is a nanoparticle medicine-enabling company. The company works together with pharma and biotech partners to reduce attrition in clinical trials and enhance their molecules' formulation performance through its nano-forming services. Its patented and scalable Controlled Expansion of Supercritical Solutions (CESS) technology produces nano-formed API particles as small as 10nm. This enables poorly soluble molecules in the pharmaceuticals pipeline to progress into clinical development by increasing their rate of dissolution and by improving their bioavailability. Its technology provides novel opportunities in many value-enhancing drug delivery applications. Geographically, the company generates maximum revenue from Europe, followed by the United States and other regions.	Contract Research & Manufacturing	$1	+2%	$109M	$92M	21.3x	(5.4x)
Herantis Pharma		Herantis Pharma PLC is a biotech company developing disease-modifying…Herantis Pharma PLC is a biotech company developing disease-modifying therapies for Parkinson’s disease. The company's current development program focuses solely on HER-096, which is a peptidomimetic molecule designed to retain the biological activity of the neuroprotective CDNF protein.	Biopharmaceuticals	$3	+70%	$69M	$66M	5657.2x	(8.8x)
Biohit		Biohit Oyj is a biotechnology company. It manufactures products that b…Biohit Oyj is a biotechnology company. It manufactures products that bind acetaldehyde, diagnostic products, and systems for diagnostic analysis for the use of research institutions, healthcare, and industry. Biohit's product portfolio consists of diagnostic tests, analysis systems, products that bind carcinogenic acetaldehyde into harmless compounds and monoclonal antibodies and service laboratory operations.	Life Sciences Tools+1	$3	-3%	$47M	$43M	2.4x	11.0x
Optomed		Optomed PLC is a Finnish medical technology company and a manufacturer…Optomed PLC is a Finnish medical technology company and a manufacturer of handheld fundus cameras and screening software. The company provides AI-based screening solutions to support diagnostic processes and early detection. It develops retinal imaging technology that is patented, clinically validated, and has approvals in all key markets, including CE, FDA and NMPA. The company's products are sold via various sales channels in over 60 countries. It has two reportable segments: Devices and Software. The majority of revenue is derived from the Software segment, which offers products for optimal management of various screening operations as well as IT solutions and services for storing, viewing and working with medical images. Geographically, it generates maximum revenue from Finland.	Medical Devices	$2	-66%	$38M	$32M	1.6x	(7.6x)
Median				$2	-1%	$89M	$79M	13.2x	(5.8x)

Financial data powered by FactSet and Morningstar. Valuation multiples as of current fiscal year. For more data, start your free trial here.